地榆升白片对胃癌化疗患者骨髓抑制及外周血常规的影响  

Effects of Diyu Shengbai Tablets on Bone Marrow Suppression and Peripheral Blood Routine in Patients Undergoing Gastric Cancer Chemotherapy

作　　者：吕云火 LYU Yunhuo(Shangrao Municipal Hospital,Shangrao Jiangxi 334000,China)

机构地区：[1]上饶市立医院,江西上饶334000

出　　处：《药品评价》2022年第1期41-44,共4页Drug Evaluation

摘　　要：目的:探讨地榆升白片治疗对胃癌化疗患者骨髓抑制及外周血常规的影响。方法:选取2016年1月至2020年12月在上饶市立医院确诊的80例胃癌患者,采用简单随机分组将患者分为观察组和对照组,每组各40例。对照组患者采用XELOX化疗方案(口服卡培他滨及静脉注射奥沙利铂)治疗,观察组采用地榆升白片联合XELOX化疗方案治疗,均持续治疗8周。分别于治疗前后,采用酶联免疫法测定血红蛋白(Hb)水平,采用全自动血液分析仪测定白细胞计数(WBC)和血小板计数(PLT);采用世界卫生组织(WHO)抗癌药物急性及亚急性毒性反应分度标准评价两组患者骨髓抑制情况;采用国际功能状态评分标准(KPS)测定治疗前后两组患者生存质量。记录两组治疗期间的副作用发生情况。结果:治疗后,观察组患者Hb、WBC、PLT水平和KPS评分明显高于对照组(P<0.05);WBC、中性粒细胞减少的骨髓抑制情况明显少于对照组(P<0.05)。观察组患者治疗期间的不良反应发生率为15.00%,与对照组的35.00%差异有统计学意义(P<0.05)。结论:地榆升白片可升高外周血常规,改善胃癌化疗患者骨髓抑制,从而改善不良反应,使患者耐受性良好。Objective:To explore the effects of diyu shengbai tablets on bone marrow suppression and peripheral blood routine in patients undergoing gastric cancer chemotherapy.Methods:A total of 80 patients with gastric cancer confirmed in Shangrao Municipal Hospital were prospective selected between January 2016 and December 2020.According to simple random grouping method,they were divided into observation group and control group,40 cases in each group.The control group was treated with XELOX chemotherapy regimen(oral capecitabine and intravenous injection of oxaliplatin),while the observation group was additionally treated with diyu shengbai tablets on the basis of control group.All were continuously treated for 8 weeks.Before and after treatment,the level of hemoglobin(Hb)was detected by enzyme-linked immunosorbent assay.The white blood cell count(WBC)and platelet count(PLT)were detected by full-automatic blood analyzer.The bone marrow suppression in both groups was assessed by World Health Organization(WHO)grading standards of anticancer drugs for acute and subacute toxic reactions.The quality of life in both groups before and after treatment was detected by karnofsky functional criteria(KPS).The occurrence of side effects during treatment in both groups was recorded.Results:After treatment,levels of Hb,WBC and PLT,and KPS score in observation group were significantly higher than those in control group(P<0.05),and bone marrow suppression of WBC and neutrophils was significantly less than that in control group(P<0.05).The differences in incidence of adverse reaction during treatment between observation group and control group were statistically significant(15.00%vs 35.00%)(P<0.05).Conclusion:Diyu shengbai tablets can increase peripheral blood routine and improve bone marrow suppression in patients undergoing gastric cancer chemotherapy,thereby alleviating adverse reactions,with better chemotherapy tolerance.

关 键 词：胃肿瘤 抗肿瘤联合化疗方案 地榆升白片 骨髓抑制 外周血常规 

分 类 号：R273[医药卫生—中西医结合]